Hematopoietic Stem Cell Transplantation Restores Na ïve T-Cell Populations in Atm-Deficient Mice and in Preemptively Treated Patients With Ataxia-Telangiectasia
Conclusion: HSCT seems to be a feasible strategy to overcome immunodeficiency and might be a conceivable strategy to avoid T-cell driven cancer in A-T at higher risk for malignancy. Naïve CD4 and CD8 T-cells counts are suitable markers for monitoring immune reconstitution post-HSCT. However, risks and benefits of HSCT in A-T have to be properly weighted.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy & Immunology | Ataxia | Cancer | Cancer & Oncology | Lymphoma | Stem Cell Therapy | Stem Cells | Transplants